Company Details

BerryBio was founded in February 2021. It is a venture-backed biotechnology startup committed to advancing the research and clinical development of targeted protein degradation (TPD). The company is headquartered in Shanghai, China, with offices in the United States. BerryBio was co-founded by scientists in the field of protein degradation, experienced clinical translational experts, and entrepreneurs familiar with the capital market. The core objective of BerryBio is to develop innovative drugs that focus on targetdifferentiation and unmet clinical needs. Our research and development projects encompass PROTAC (bi-functional small molecule intracellular protein degradation technology), smLYTAC (bi-functional small molecule targeted lysosomal degradation of extracellular and cell membranes proteins), and Molecular Glue (a targeted degradation technology based on innovative monovalent small moleclues). BerryBio currently has several pipelines under development, primarily focusing on the field of oncology.

PROTAC (Proteolysis-targeting chimera) is a new modality that attracts significant attention recently. The PROTAC technology makes use of the cell’s native protein degradation machinery to mark the target proteins and trigger their degradation. As a result, the target protein is irreversibly removed from the system. This new mechanism of “degradation” is fundamentally different from the traditional “inhibition”, which is mainly through high-affinity functional target occupancy. Compared to the traditional inhibition, this new modality has the following advantages:
1) Expand the space of disease targets that can be used for development, making it possible to develop drugs against "non-druggable" targets
2) Leveraging the body's own "catalytic reaction" instead of "inhibiting" the activity of the target can significantly reduce the drug dosage.
3) Greatly improve the selectivity compared to traditional inhibitors.
4) Fundamentally solve the problem of drug resistance